Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups
- PMID: 27529519
- DOI: 10.1002/cncr.30220
Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups
Abstract
Background: To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on the genetic changes occurring during a lifetime.
Methods: This study analyzed the relation between age and genetics from birth to 100 years in 5564 patients with de novo AML diagnosed from 1998 to 2012 (1192 patients from nationwide pediatric studies [AML Berlin-Frankfurt-Münster studies 98 and 2004] and 4372 adults registered with the Munich Leukemia Laboratory).
Results: The frequencies of cytogenetic subgroups were age-dependent. Favorable subtypes (t(8;21), inv(16)/t(16;16), and t(15;17)) decreased in general from the pediatric age group (2 to < 18 years; 33%) to the oldest groups (<5% for > 70 years; P < .0001). Unfavorable cytogenetics (-7/del(7), -5/del(5q) or 5p, inv(3)/t(3;3), t(6;9), complex karyotype, 12p, 17p, and 11q23/mixed-lineage leukemia aberrations, excluding t(9;11)) were frequent (42%) in infants (<2 years), had a low frequency in children and young adults (<22%), and increased in frequency up to 36% in patients older than 85 years (P = .01). This was even more significant for complex karyotypes (P ≤ .0001), which also showed a strong increase in the absolute age-specific incidence with age. Interestingly, the frequency of 11q23 abnormalities decreased from infants to older patients. The proportion of clinically relevant molecular aberrations of CCAAT/enhancer binding protein α, nucleophosmin (NPM1), and NPM1/fms-related tyrosine kinase 3-internal tandem duplication increased with age.
Conclusions: Altogether, with the exclusion of infants, a significant decrease in the proportion of favorable cytogenetic subtypes and an increase in unfavorable cytogenetics were observed with increasing age. These findings indicate different mechanisms for the pathogenesis of AML; these different mechanisms also suggest directions for etiological research and contribute to the more unfavorable prognosis with increasing age. Cancer 2016;122:3821-3830. © 2016 American Cancer Society.
Keywords: acute myeloid leukemia; adults; age groups; cytogenetics; molecular genetics; pediatric.
© 2016 American Cancer Society.
Similar articles
-
Cytogenetic profile of a large cohort of Tunisian de novo acute myeloid leukemia.Hematology. 2012 Jan;17(1):9-14. doi: 10.1179/102453312X13221316477417. Hematology. 2012. PMID: 22549442
-
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.J Clin Oncol. 2010 Jun 1;28(16):2682-9. doi: 10.1200/JCO.2009.25.6321. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439630 Clinical Trial.
-
Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.J Clin Oncol. 2010 Jun 1;28(16):2674-81. doi: 10.1200/JCO.2009.24.8997. Epub 2010 May 3. J Clin Oncol. 2010. PMID: 20439644
-
[Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):1063-8. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010. PMID: 20723330 Review. Chinese.
-
Cytogenetics of pediatric acute myeloid leukemia.Eur J Haematol. 2009 Nov;83(5):391-405. doi: 10.1111/j.1600-0609.2009.01308.x. Epub 2009 Jun 25. Eur J Haematol. 2009. PMID: 19563518 Review.
Cited by
-
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.Eur J Med Genet. 2023 Dec;66(12):104869. doi: 10.1016/j.ejmg.2023.104869. Epub 2023 Oct 29. Eur J Med Genet. 2023. PMID: 38174649 Free PMC article. Review.
-
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial.Lancet Haematol. 2019 Jan;6(1):e29-e37. doi: 10.1016/S2352-3026(18)30182-0. Epub 2018 Dec 10. Lancet Haematol. 2019. PMID: 30545576 Free PMC article. Clinical Trial.
-
High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.Blood Adv. 2022 Oct 11;6(19):5570-5581. doi: 10.1182/bloodadvances.2022007544. Blood Adv. 2022. PMID: 35788257 Free PMC article.
-
Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.Genes (Basel). 2021 Jun 17;12(6):924. doi: 10.3390/genes12060924. Genes (Basel). 2021. PMID: 34204358 Free PMC article. Review.
-
Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia.Front Oncol. 2024 Apr 24;14:1340909. doi: 10.3389/fonc.2024.1340909. eCollection 2024. Front Oncol. 2024. PMID: 38720804 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous